Sunshine Biopharma Inc.
2.82
-0.07 (-2.42%)
At close: Jan 14, 2025, 3:59 PM
2.84
0.71%
After-hours Jan 14, 2025, 05:46 PM EST
undefined%
Bid 2.75
Market Cap 7.64M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -127.9
PE Ratio (ttm) -0.02
Forward PE n/a
Analyst Buy
Ask 2.85
Volume 74,118
Avg. Volume (20D) 706,270
Open 2.90
Previous Close 2.89
Day's Range 2.76 - 2.93
52-Week Range 2.11 - 572.00
Beta undefined

About SBFM

Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast c...

Sector Healthcare
IPO Date Feb 15, 2022
Employees 44
Stock Exchange NASDAQ
Ticker Symbol SBFM

Analyst Forecast

According to 1 analyst ratings, the average rating for SBFM stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 431.91% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Sunshine Biopharma Inc. is scheduled to release its earnings on Mar 27, 2025, before market opens.
Analysts project revenue of $15.50M, reflecting a 101.82% YoY growth and earnings per share of 26.8, making a -122.33% decrease YoY.
1 month ago · Source
+11.32%
Sunshine Biopharma shares are trading higher after... Unlock content with Pro Subscription
7 months ago · Source
+37.89%
Sunshine Biopharma shares are trading higher after Texas Congressman Roger Williams disclosed a purchase in the company.